![]() |
Dinner and Registration: 6:00PM - 6:30PM CT Registration for this program is now closed. |
Program Overview:
Patients with heart failure with reduced ejection fraction (HFrEF) and recent worsening heart failure (WHF) have high rates of death and hospitalization despite the use of guideline-directed medical therapy (GDMT). Moreover, the administration of GDMT and the achievement of target doses are often difficult in these patients. Therefore, patients with HFrEF and recent WHF events are at significantly increased risk, underscoring the need for new therapies for this large subgroup of patients with HFrEF. New and emerging novel agents, with distinct mechanisms of action, have demonstrated improved clinical outcomes in these patients, and clinicians must be able to not only identify appropriate patients for these therapies--personalizing treatment based on the patient’s profile--but also utilize these therapies effectively in practice. Regardless of whether HF therapies are initiated in or out of the hospital, patient education and self-care are critical components of overall patient management. Preventive strategies such as risk factor control, treatment of comorbidities, and emphasis on adherence to the medication regimen are essential. Hospitalized patients with WHF require well-developed and executed transitions of care to prevent re- hospitalization and facilitate improved patient outcomes. Therefore, in this program, HF experts will explain the challenges in managing patients with HFrEF and recent WHF, identify the roles for new and emerging therapies, and describe best practices to prevent adverse HF-related events. |
|
Educational Objectives:
Accreditation & Credit Designation:
|